LIMN NASDAQ
Liminatus Pharma, Inc. Class A Common Stock
1W: +33.7%
1M: +12.5%
3M: +7.4%
YTD: -61.6%
1Y: -96.1%
$0.17
-0.08 (-31.14%)
Weekly Expected Move ±7.4%
$0
$0
$0
$0
$0
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Smart Money Score
No convergence signal
Key Statistics
Market Cap$4.5M
52W Range0.132-33.66
Volume24,930,506
Avg Volume3,991,262
Beta0.74
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOChris Kim
Employees3
SectorHealthcare
IndustryBiotechnology
IPO Date2025-05-01
Websiteliminatuspharma.com
6 Centerpointe Drive
La Palma, CA 90623
US
La Palma, CA 90623
US
213 273 5453
About Liminatus Pharma, Inc. Class A Common Stock
Liminatus Pharma, Inc. operates as a clinical-stage immuno-oncology company that develops novel cancer therapies. The company is based in LA Palma, California.
Latest News
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's Intraday Session
Liminatus Pharma Announces Proposed Merger with InnocsAI to Expand Oncology Cell Therapy Pipeline
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Lemons II Philip Way | 0 | — | 2025-07-10 | |
| Baek Richard JaiHwan | 0 | — | 2025-07-10 | |
| Iris Acquisition Hol | 0 | — | 2025-04-30 | |
| KH Feelux Co., Ltd | 0 | — | 2025-04-30 | |
| Valetudo Therapeutic | 0 | — | 2025-04-30 |